Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Up 162.2% in December

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 2,250,000 shares, a growth of 162.2% from the December 15th total of 858,100 shares. Approximately 4.1% of the shares of the stock are sold short. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is currently 2.0 days.

Shares of PULM stock opened at $0.40 on Friday. The business’s fifty day moving average price is $0.58 and its 200 day moving average price is $0.75. Pulmatrix has a 1-year low of $0.39 and a 1-year high of $3.04. The firm has a market capitalization of $22.44 million, a PE ratio of -1.11 and a beta of 1.28.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Wednesday, November 10th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.08). The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $2.48 million. Pulmatrix had a negative net margin of 283.61% and a negative return on equity of 34.73%. On average, equities research analysts anticipate that Pulmatrix will post -0.39 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of PULM. Renaissance Technologies LLC grew its holdings in Pulmatrix by 19.0% in the second quarter. Renaissance Technologies LLC now owns 2,848,391 shares of the biotechnology company’s stock valued at $2,962,000 after purchasing an additional 455,233 shares during the last quarter. Vanguard Group Inc. grew its holdings in Pulmatrix by 17.4% in the second quarter. Vanguard Group Inc. now owns 2,047,588 shares of the biotechnology company’s stock valued at $2,130,000 after purchasing an additional 303,286 shares during the last quarter. State Street Corp acquired a new stake in Pulmatrix in the second quarter valued at $288,000. Morgan Stanley grew its holdings in Pulmatrix by 1,563.9% in the second quarter. Morgan Stanley now owns 265,448 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 249,495 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Pulmatrix by 68.4% in the second quarter. Geode Capital Management LLC now owns 487,999 shares of the biotechnology company’s stock valued at $507,000 after purchasing an additional 198,146 shares during the last quarter. 13.65% of the stock is currently owned by institutional investors.

Separately, Zacks Investment Research lowered Pulmatrix from a “buy” rating to a “hold” rating in a report on Thursday.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Recommended Story: Federal Reserve

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.